Controversies and challenges of vaccination: an interview with Elizabeth Miller by Elizabeth Miller
QUESTION AND ANSWER Open Access
Controversies and challenges of vaccination:
an interview with Elizabeth Miller
Elizabeth Miller
Abstract
Although strong evidence exists that the benefits of vaccination by far outweigh potential adverse events, controversy
still exists. This has led opponents of vaccination to question its safety, efficacy and necessity. In an interview with
Professor Elizabeth Miller, we discuss the continuum of beliefs held by vaccine refusers and hesitators, the resulting
health consequences, and ways in which health professionals and industry regulators can help promote transparency
to better convey the substantial health benefits of vaccination.
Introduction
Professor Miller (Fig. 1) is a Consultant Epidemiologist
at the Immunisation Hepatitis and Blood Safety Depart-
ment, Public Health England (PHE) in Colindale North,
West London, and has a long standing interest in the risks
and benefits of vaccination programmes. She leads a re-
search team that undertakes trials of new vaccines or new
schedules for existing vaccines and has been involved with
trials of acellular pertussis, measles, mumps and rubella
(MMR), Haemophilus influenzae type B (Hib), meningo-
coccal C vaccines and, more recently, the pneumococcal
and HPV vaccines. In collaboration with colleagues at
PHE, she has conducted several vaccine safety studies to
investigate the associations between MMR and autism,
convulsions and “immune overload”, H1N1 vaccine and
narcolepsy, thiomersal and developmental delay, oral polio
vaccine and intussusception, and meningococcal C conju-
gate vaccine and nephrotic syndrome, among others. She
was one of the founder members of the World Health
Organization (WHO) Global Advisory Committee on
Vaccine Safety and served for 6 years as a member of the
WHO Strategic Advisory Group of Experts.
1) As a world-leading expert in immunization research you
have become known as a key advisor on vaccination policies.
Can you explain what attracted you to this area of research?
I first became involved in vaccine research in 1978,
when I joined the then Public Health Laboratory Service
as a medical epidemiologist. I worked on the large post-
licensure safety and efficacy studies of pertussis vaccines
that were being conducted following the collapse of the
UK whooping cough immunisation programme in the
mid-1970s. This massive decline in vaccine coverage was
the result of allegations that the vaccine caused brain
damage based on reports of children who developed
neurological conditions after vaccination. These safety
concerns were amplified by claims that the vaccine was
also largely ineffective in protecting against the disease.
Massive nationwide epidemics of whooping cough
followed the collapse in coverage and, while it was rela-
tively easy to demonstrate the efficacy of the vaccine,
safety studies were more difficult to perform. Back then,
before the advent of desk top computers and the inter-
net, it was quite a challenge to conduct large epidemio-
logical studies to test whether a temporal association
between vaccination and the development of a rare clin-
ical condition was due to chance or was evidence of a
causal connection. It therefore took several years to con-
duct the prospective cohort and case control studies that
eventually confirmed the safety of the vaccine and
allowed coverage to be restored.
The next vaccine safety scare to hit the UK occurred
in the 1990s, when claims were made that MMR caused
autism. By this time, it was possible to remotely access
computerized health records and link these with
immunization records, which meant that retrospective
cohort studies could be rapidly undertaken with minimal
cost. Over the last two decades, our research team has
conducted many studies of vaccine safety using these
large linked databases and employing a novel statistical
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method that we developed to improve analytic efficiency
and minimize confounding – a potential source of bias
in any observational study of association. I have found
this vaccine safety research not only intellectually chal-
lenging but also very rewarding in that its results can
directly inform vaccine policy and the risk-benefit evalu-
ation implicit in every individual’s decision to accept a
vaccine.
2) What are the controversies regarding vaccines?
Vaccines differ from other medications as they are given
to millions of healthy individuals, usually children, to
prevent diseases that may no longer pose an immediate
threat. Concern about vaccine safety is therefore per-
fectly legitimate and, when potential safety signals arise,
they must be investigated promptly and rigorously.
Many of the concerns about vaccine side effects have
arisen as a result of reports of a temporal association
between administration of a vaccine and development of
a rare disease for which the cause is currently unknown.
Such case reports are still the way that most safety
signals are generated; indeed, health professionals and
parents are encouraged to report any side effects that
they suspect may have been caused by a vaccine to au-
thorities such as the Centers for Disease Control and
Prevention (CDC) in the US or the Medicines and
Healthcare products Regulatory Agency (MHRA) in the
UK.
In other instances, signals are generated from eco-
logical associations, where an increase in the incidence
of a disease is noticed to coincide with introduction of a
vaccine. Examples of vaccine safety concerns that have
arisen in this way are the alleged association between
the combined MMR vaccine and autism, which was
based on both a reported temporal link for some cases
and a suggested ecologic association. This developed
into a “controversy”, as despite sound epidemiological
studies showing no excess of autism onsets after MMR
vaccine, there remained a vocal lobby that did not accept
the evidence.
The reasons why scientific evidence on vaccine safety
is rejected by the so-called ‘anti-vaxxers’ are complex
and varied. They include distrust of the scientific
‘establishment’ who generally promotes vaccination,
albeit based on careful risk-benefit analyses, suspicion
that those conducting vaccine safety studies are in the
pay of the pharmaceutical industry, sincerely held per-
sonal belief that their child was damaged by a vaccine,
or pseudoscientific beliefs such that vaccination is un-
natural and it is better for a child to experience the real
disease or that giving several vaccines to a young child
can ‘overload the immune system’. Despite strong scien-
tific arguments against the immune overload hypothesis
and epidemiological studies showing no increased risk of
infections after multiple vaccinations, this idea may seem
plausible to parents who then hesitate to vaccinate their
infant believing that deferral until an older age may be
in their best interests. The concept of vaccine hesitancy
is one that is now gaining currency as it recognizes that
there is a continuum between those who accept and
those who refuse vaccination and that it is not helpful to
characterize all of the latter as anti-vaxxers.
3) What are the health consequences of refusing
vaccinations and what are the implications beyond
those who do so?
An implacable rejection of vaccination, despite strong
evidence of its safety, is damaging. It places the individ-
ual at increased risk of disease and also of exposing vul-
nerable contacts. For example, in a measles outbreak in
San Diego in which the index case was an ‘intentionally
unvaccinated’ child who contracted the disease while
travelling abroad, 75 % of the secondary cases were
similarly unvaccinated due to refusal, with one
hospitalization of an infected infant who was too young
to be vaccinated. In addition to the clinical conse-
quences of such outbreaks, there are economic impacts
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because of the extensive public health measures that
need to be put in place to limit transmission and protect
vulnerable contacts. However, the consequences can be
even more far reaching than this, as the promulgation of
anti-vaccine views via websites and the media can lead
to a decline in vaccine acceptance among others who are
not, in principle, opposed to vaccination. In the case of
the MMR controversy, for example, sustained interest in
the alleged association by the British media with exten-
sive coverage of the unsubstantiated claims of the anti-
vaccine lobby and scant attention to the actual scientific
evidence resulted in a critical fall in MMR vaccine cover-
age in the UK. As a result, measles, which is highly
infectious and can exploit even a small decline in popu-
lation immunity, returned with savage consequences.
After an interval of 14 years with no acute measles
deaths, the resurgence associated with MMR vaccine
refusal led to the deaths of two immunocompromised
children who could not be vaccinated and therefore
contracted the disease. Within the European region, re-
fusal or hesitancy to accept the MMR vaccine because of
unfounded safety concerns has been one of the factors
behind its continuing failure to attain the region’s mea-
sles elimination goal, initially set for 2010, then deferred
until 2015.
4) How should the risks of not vaccinating be
communicated?
There is no blanket approach to communicating with
parents who refuse or are hesitant to vaccinate. In fact,
some research has suggested that emphasizing the dan-
gers of not vaccinating may be counterproductive. In a
controlled trial in the US, parents were randomly allo-
cated to a control group or to receive 1 of 4 interven-
tions, namely (1) information about the lack of evidence
that MMR causes autism from the CDC, (2) information
about the dangers of the diseases prevented by MMR,
(3) images of children with diseases prevented by the
MMR vaccine, and (4) a dramatic narrative about an
infant who almost died of measles. None of the interven-
tions increased parents’ intent to vaccinate. Further-
more, amongst those with the most negative opinions,
the interventions actually increased misperceptions or
reduced vaccination intention. Since parents rate their
children’s doctor as their most trusted source of vaccine
safety information, it is important that paediatricians
and general practitioners have access to the most up-to-
date information. In the UK, for example, during the
MMR/autism controversy, the Department of Health
posted each new safety study on its website as it was
published, together with up-to-date information on dis-
ease risks.
Tailoring the message to the individual is important
as well. In an attempt to provide health professionals
with a framework for communicating with parents,
researchers have identified five distinct parental atti-
tudes, representing a continuum of beliefs regarding
vaccination. There are the ‘unquestioning acceptors’
(30–40 %), who believe in the benefits of vaccination
and trust their healthcare provider to have their child’s
best interests at heart, and the ‘cautious acceptor’
(25–35 %), who have some minor concerns but never-
theless proceed with vaccination following a brief dis-
cussion on side effects and disease risks. The ‘hesitant’
group (20–30 %) comprises those who have significant
concerns about vaccine risks. For this group, trust in their
doctor or nurse is key and, if their questions are answered
satisfactorily and completely by knowledgeable health pro-
fessionals, they will proceed with vaccination. The ‘late or
selective vaccinator’ (2–27 %) group has specific concerns
about one vaccine or alleged phenomena, such as immune
overload, and are generally knowledgeable. This group
needs the most time, with detailed information on the
risks and benefits of vaccination and, if necessary, another
appointment to reconsider their decision. The outright
‘refuser’ of all vaccines generally comprise less than <2 %
and are often motivated by their religious, philosophical
or alternative beliefs. For this group, even referral to a spe-
cialist immunization clinic where they can have dedicated
time with experts is unlikely to change their attitude. This
analytic framework supports the concept of vaccine
hesitancy and makes useful distinctions between the
tiny minority who are implacably opposed to vaccin-
ation and the broader group of vaccine refusers who
can have their views modified with appropriate discus-
sion and information.
5) Should vaccination be compulsory?
Making vaccination compulsory by law is often seen as a
way of improving compliance and dealing with the prob-
lem of vaccine hesitancy or refusal. While individual
freedom of choice is an important principle, those who
refuse vaccination not only pose a risk to themselves but
also to others. The philosopher JS Mill, while a staunch
proponent of individual liberty, recognized in his essay
On Liberty in 1859, that “the only purpose for which
power can be rightfully exercised over any member of a
civilized community, against his will, is to prevent harm
to others”, thus presciently providing an ethical justifica-
tion for mandatory vaccination. Moreover, vaccine re-
fusers are now often seen as ‘free loaders’ – exercising
their rights to refuse vaccination safe in the knowledge
that the risk to their own child is low because of the
herd immunity provided by others who have their child
vaccinated. In the European Union, 14 of the 27 countries
have one or more mandatory vaccination programmes,
with the legal consequences of failure to comply ranging
from punitive measures such as pecuniary penalties,
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difficulty to attend public schools or even penal conse-
quences for the parents, to milder disincentives such as
just necessitating a formal ‘opt-out’ on religious or philo-
sophical grounds. The rigour with which mandatory vac-
cination is enforced also varies and, overall, there is no
clear evidence from European countries that mandatory
vaccination necessarily achieves high coverage. In the US
and Australia, however, compulsory vaccination has con-
tributed to the success of immunisation programmes, but
the balance between individual freedoms and public bene-
fits is a fine judgement and not all countries will make the
same decision. In countries such as Sweden, Norway,
Denmark, the Netherlands, and the UK, compulsory im-
munisation is unlikely to be acceptable and indeed high
coverage has been achieved through other approaches.
6) What can be done to increase transparency in research
funded by pharmaceutical companies, and is enough
being done to ensure that data from vaccine trials are
being adequately reported, particularly regarding any
adverse outcomes?
There have been significant changes to the regulatory
framework in recent years which have ensured that man-
ufacturers of any medicinal product, including vaccines,
operate in a more transparent manner, with improved
systems for detection of adverse events. Firstly, all those
conducting clinical trials of vaccines and therapeutic
drugs are encouraged to register them on a publically ac-
cessible website such as ClinicalTrials.gov. In the US,
the Food and Drug Administration Amendment Act re-
quires this by law and the International Committee of
Medical Journal Editors (ICMJE) makes trial registration
a condition of the publication of clinical trial results.
The purpose is partly to ensure that potentially eligible
participants are made aware of trials that may be of
interest to them and are kept informed of the results,
but also to reduce bias in outcome reporting. When an
unexpected but serious adverse event occurs that might
possibly be related to the vaccine or drug (termed a sus-
pected unexpected serious adverse reaction), there is
now a requirement to notify the licensing authority
within 7 days so that information can be rapidly collated
across different trials using the same product to assess
whether this constitutes a safety signal. Hiding unfavour-
able safety results in a trial is not an option as the licens-
ing authority can audit the conduct of the trial and the
compliance of the investigators with Good Clinical
Practice and the regulatory framework. As part of the
licensing process, manufactures must also submit a Risk
Management Plan that identifies possible risks of their
product, including any potential pre-licensure safety sig-
nals, together with a mitigation strategy to reduce the
risk. Thus, when the second generation of rotavirus vac-
cines was licensed, manufacturers were required to
conduct large post-marketing studies to assess the risk
of intussusception, as this rare side effect was the cause
of the withdrawal of the first licensed rotavirus vaccine.
With novel statistical methods, such as the self-
controlled case series, and the increasing availability of
large linked databases, such studies can now be con-
ducted rapidly and with minimal bias.
Despite these improvements, no risk management plan
could anticipate a rare and completely unexpected reac-
tion, for example, narcolepsy following the AS03 adju-
vanted H1N1 pandemic influenza vaccine, which first
came to light as a result of observant sleep physicians
who noted an increase in referral of cases, many of
whom had recently been vaccinated. While pre-licensure
trials were necessarily limited in size due to the urgency
of getting the pandemic vaccine to the population in
time, with a risk as low as 1 in 55,000 largely concen-
trated in children and adolescents, conducting a pre-
licensure trial large enough to detect such a reaction
would not have been feasible.
While it is important to convey the huge benefits of
vaccination, it is also necessary to honestly acknowledge
that the absolute safety of a new vaccine can only be
confirmed after it has been given to hundreds of thou-
sands of individuals and that the decision to vaccinate is
a risk-benefit judgement that requires full informed
consent.
7) Where can I find out more?
See reference list [1–16].
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